Sort   by:  
 Page size 
TranscriptomicsComparative genomic hybridization by array of east haploid and heterozygous essential deletion pools treated with compounds synergistic with fluconazole to identify sensitive and resistant mutants
The haploid and the heterozygous essential S.cerevisiae deletion pools were grown in the presence of compounds that we found to be synergistic with fluconazole. We also treated the deletion pools with combinations of those drugs and fluconazole to interrogate the mechanism of action of the drug inte...
ORGANISM(S): Saccharomyces cerevisiae 
2011-09-07 | E-MTAB-394 | biostudies-arrayexpress
MetabolomicsTranscriptional Shift and Metabolic Adaptations during Leishmania Quiescence Using Stationary Phase and Drug Pressure as Models

Microorganisms can adopt a quiescent physiological condition which acts as a survival strategy under unfavourable conditions. Quiescent cells are characterized by slow or non-proliferation and deep down-regulation of processes related to biosynthesis. Although quiescence has been described mostly...

2022-02-23 | MTBLS4046 | MetaboLights
GenomicsEmergent gene expression responses to drug combinations predict higher-order drug interactions
Emergent gene expression responses to drug combinations predict higher-order drug interactions
PRJNA575231 | ENA
ProteomicsProteomics to determine metallodrug targets and optimal drug combinations
The FITExP profiling approach was used to identify protein hits from cells incubated with RAPTA-T or RAPTA-EA. Validation experiments with paclitaxel and cisplatin underlined the reliability of the method and hit lists for both test compounds (and?) gave physiologically viable anti-cancer mechanisms...
ORGANISM(S): Homo sapiens (Human) 
2018-02-09 | PXD005766 | Pride
Drug targets Fitexp Cancer 
ProteomicsA structure-based modelling approach identifies effective drug combinations for RAS-mutant acute myeloid leukemia
Abstract Mutations activating RAS/RAF/MEK/ERK signaling are associated with poor outcome in acute myeloid leukemia (AML), but therapeutic targeting of this pathway is challenging. Here, we employ a structure-based, dynamic RAS pathway model to successfully predict RAF inhibitor (RAFi) combinations ...
ORGANISM(S): Homo sapiens (Human) 
2026-06-24 | PXD063606 | Pride
Drug combinations Ras-mutant acute myeloid leukemia. Structure-based modelling 
MetabolomicsEffect of Pro-longevity drugs on Lipid profile, link between lipid signalling and longevity
We report the effect of four lifespan modifying drugs and of combinations of these drugs on lipid profile in Caenorhabditis elegans. We investigated drug-drug interactions and identified beneficial drug interactions between drugs selected to target synergistic longevity mechanisms and pathways. We e...
2018-06-08 | MTBLS648 | MetaboLights
GenomicsA network-based trans-omics approach for predicting synergistic drug combinations
A network-based trans-omics approach for predicting synergistic drug combinations
PRJNA1068432 | ENA
ProteomicsSolubility based mechanistic profiling of combinatorial drug therapy
Acute myeloid leukemia (AML) poses a major clinical challenge due to its genetic diversity, relapse rates, and chemotherapy toxicity. While rational drug combinations improve efficacy, their mechanisms remain poorly understood. We introduce CoPISA (Proteome Integral Solubility/Stability Alteration A...
ORGANISM(S): Homo sapiens (Human) 
2026-02-12 | PXD066812 | Pride
Combination therapy Acute myeloid leukaemia Proteome integral solubility alteration assay for combinations Copisa 
GenomicsRNA-seq analysis of SUM149 inflammatory breast cancer cells treated with computationally predicted drug combinations
RNA-seq analysis of SUM149 inflammatory breast cancer cells treated with computationally predicted drug combinations
PRJNA1467751 | ENA
GenomicsTranscriptomic profiles of tissues from rats treated with drug combinations [Study 1]
Transcriptomic profiles of tissues from rats treated with drug combinations [Study 1]
PRJNA488229 | ENA
Sort   by:  
 Page size